STAMPEDE Investigators
Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992-2003
STAMPEDE Investigators, Parikh O, O'Sullivan J, Omlin A, Nikapota A, Lydon A, Gibbs S, Gale J, Capaldi L, Birtle A, Beesley S, Protheroe A, Rudman S, Srihari N, James N, Parmar M, Sydes M, Zarkar A, Wylie J, Wallace J, Wagstaff J, Tolan S, Tanguay J, Simms M, Brown J, Russell J, Rush H, Cross W, Cook A, Chowdhury S, Calvert J, Brawley C, Attard G, Amos C, Hoyle A, Ingleby F, Ali A, Dearnaley D, Douis H, Gilbert D, Ritchie A, Parker C, Millman R, Matheson D, Mason M, Malik Z, MacNair A, Langley R, Jones R, Gillessen S, Clarke N. Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992-2003. Ann Oncol 2020; 31:442.
31.01.2020Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992-2003
31.01.2020Ann Oncol 2020; 31:442
STAMPEDE Investigators, Parikh O, O'Sullivan J M, Omlin Aurelius, Nikapota A, Lydon A, Gibbs S, Gale J, Capaldi L, Birtle A, Beesley S, Protheroe A, Rudman S, Srihari N N, James N D, Parmar M K B, Sydes M R, Zarkar A, Wylie J, Wallace J, Wagstaff J, Tolan S, Tanguay J S, Simms M, Brown J, Russell J M, Rush H, Cross W, Cook A, Chowdhury S, Calvert J, Brawley C D, Attard G, Amos C L, Hoyle A, Ingleby F C, Ali A, Dearnaley D P, Douis H, Gilbert D, Ritchie A W S, Parker C C, Millman R, Matheson D, Mason M D, Malik Z, MacNair A, Langley R E, Jones R J, Gillessen S, Clarke N W
Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer
Hoyle A, Aebersold D, Jones R, Matheson D, Millman R, Mason M, Ritchie A, Russell M, Douis H, Parmar M, Sydes M, Clarke N, Gillessen Sommer S, Ingleby F, Ali A, James N, Cook A, Parker C, de Bono J, Attard G, Chowdhury S, Cross W, Dearnaley D, Brawley C, Gilson C, STAMPEDE Investigators. Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer. Eur Urol 2019; 76:719-728.
23.08.2019Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer
23.08.2019Eur Urol 2019; 76:719-728
Hoyle Alex P, Aebersold Daniel M, Jones Rob J, Matheson David, Millman Robin, Mason Malcolm D, Ritchie Alastair W S, Russell Martin, Douis Hassan, Parmar Mahesh K B, Sydes Matthew R, Clarke Noel W, Gillessen Sommer Silke, Ingleby Fiona, Ali Adnan, James Nicholas D, Cook Adrian, Parker Christopher C, de Bono Johann S, Attard Gerhardt, Chowdhury Simon, Cross William R, Dearnaley David P, Brawley Christopher D, Gilson Clare, STAMPEDE Investigators
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol
STAMPEDE Investigators, Protheroe A, Peedell C, Parikh O, O'Sullivan J, Nikapota A, Lester J, McLaren D, Hughes R, Gilbert D, Gibbs S, Rudman S, Shaffer R, Sheehan D, James N, Parmar M, Wagstaff J, Varughese M, Tsang D, Tolan S, Sundar S, Strebel R, Srihari N, Simms M, Gale J, Ford D, Evans L, Malik Z, Gillessen Sommer S, Cross W, Chowdhury S, Attard G, de Bono J, Dearnaley D, Clarke N, Mason M, Spears M, Jones R, Parker C, Ritchie A, Choudhury A, Chakraborti P, Capaldi L, Brock S, Birtle A, Gilson C, Amos C, Matheson D, Millman R, Russell J, Sydes M. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Ann Oncol 2018; 29:1235-1248.
01.05.2018Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol
01.05.2018Ann Oncol 2018; 29:1235-1248
STAMPEDE Investigators, Protheroe A, Peedell C, Parikh O, O'Sullivan J, Nikapota A, Lester J F, McLaren D, Hughes R, Gilbert D C, Gibbs S, Rudman S M, Shaffer R, Sheehan D, James N D, Parmar M K B, Wagstaff J, Varughese M, Tsang D, Tolan S, Sundar S, Strebel R, Srihari N, Simms M, Gale J, Ford D, Evans L, Malik Z I, Gillessen Sommer Silke, Cross W, Chowdhury S, Attard G, de Bono J S, Dearnaley D P, Clarke N W, Mason M D, Spears M R, Jones R, Parker C C, Ritchie A W S, Choudhury A, Chakraborti P, Capaldi L, Brock S, Birtle A, Gilson C, Amos C, Matheson D, Millman R, Russell J M, Sydes M R
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
STAMPEDE Investigators, McPhail N, McKinna F, Malik Z, Lester J, Hoskin P, Hingorani M, Gray E, Gale J, Ferguson C, Chakraborti P, Money-Kyrle J, O'Sullivan J, Sydes M, Parmar M, Zarkar A, Wylie J, Wagstaff J, Thomas C, Srihari N, Robinson A, Protheroe A, Parikh O, Brock S, Bowen J, Matheson D, Jones R, Gilson C, Amos C, Ritchie A, Dearnaley D, Mason M, Clarke N, Spears M, de Bono J, Millman R, Attard G, Birtle A, Aung S, Adab F, Brawley C, Berthold D, Russell J, Parker C, Gillessen Sommer S, Cross W, Chowdhury S, James N. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. N Engl J Med 2017; 377:338-351.
03.06.2017Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
03.06.2017N Engl J Med 2017; 377:338-351
STAMPEDE Investigators, McPhail Neil, McKinna Fiona, Malik Zafar I, Lester Jason F, Hoskin Peter J, Hingorani Mohan, Gray Emma, Gale Joanna, Ferguson Catherine, Chakraborti Prabir, Money-Kyrle Julian, O'Sullivan Joe, Sydes Matthew R, Parmar Mahesh K B, Zarkar Anjali, Wylie James, Wagstaff John, Thomas Carys, Srihari Narayanan N, Robinson Angus, Protheroe Andrew, Parikh Omi, Brock Susannah, Bowen Jo, Matheson David, Jones Rob J, Gilson Clare, Amos Claire L, Ritchie Alastair W S, Dearnaley David P, Mason Malcolm D, Clarke Noel W, Spears Melissa R, de Bono Johann S, Millman Robin, Attard Gerhardt, Birtle Alison J, Aung San, Adab Fawzi, Brawley Chris, Berthold Dominik R, Russell J Martin, Parker Christopher C, Gillessen Sommer Silke, Cross William R, Chowdhury Simon, James Nicholas D